Add like
Add dislike
Add to saved papers

Risk of Adverse cardiovascular outcomes among persons living with HIV and nonalcoholic fatty liver disease: a multicenter matched cohort study.

AIDS 2023 March 7
OBJECTIVE: To examine and compare the risk of major adverse cardiovascular events (MACE) between persons living with HIV (PLWH) with and without nonalcoholic fatty liver disease (NAFLD).

DESIGN: Population-based, multicenter, retrospective cohort study.

METHODS: Data on PLWH between January 1, 2008, and December 31, 2020 were extracted from the TriNetX database. Primary outcomes were defined as the first incidence of myocardial infarction (MI), MACE, new-onset heart failure (HF), and a composite of cerebrovascular disease. Cox models were used to obtain hazard ratios (HR) and 95% confidence intervals (CI).

RESULTS: A total of 151,868 patients were identified as having HIV. After exclusions, 4969 patients were identified as having NAFLD. Of them, 4463 (90%) were propensity matched to a non-NAFLD control. Patients with NAFLD were older(42.9 vs. 40.8 years). Among the NAFLD cohort, most participants were male and had a smoking history (12.3% vs. 9.8%) than non-NAFLD. The mean follow-up was 4.8 ± 1.1 years for the NAFLD group and 5.3 ± 1.2 years for the non-NAFLD group. The risk of all outcomes was statistically significantly higher in NAFLD patients compared to those without NAFLD: MI (HR, 1.49, 95% CI, 1.11-2.01) MACE (HR, 1.49, 95% CI, 1.25-1.79), HF (HR, 1.73, 95% CI 1.37 - 2.19) and, cerebrovascular diseases (HR, 1.25, 95% CI, 1.05-1.48) and sensitivity analysis showed similar magnitude to the one generated in the primary analysis.

CONCLUSIONS: Patients with NAFLD have an elevated risk of cardiovascular events. The results indicate the need for targeted efforts to improve awareness of CVEs risk in PLWH with NAFLD.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app